dalteparin has been researched along with Bacterial Infections in 1 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Bacterial Infections: Infections by bacteria, general or unspecified.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Villa, E | 1 |
| Cammà , C | 1 |
| Marietta, M | 1 |
| Luongo, M | 1 |
| Critelli, R | 1 |
| Colopi, S | 1 |
| Tata, C | 1 |
| Zecchini, R | 1 |
| Gitto, S | 1 |
| Petta, S | 1 |
| Lei, B | 1 |
| Bernabucci, V | 1 |
| Vukotic, R | 1 |
| De Maria, N | 1 |
| Schepis, F | 1 |
| Karampatou, A | 1 |
| Caporali, C | 1 |
| Simoni, L | 1 |
| Del Buono, M | 1 |
| Zambotto, B | 1 |
| Turola, E | 1 |
| Fornaciari, G | 1 |
| Schianchi, S | 1 |
| Ferrari, A | 1 |
| Valla, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacokinetics and Pharmacodynamics of Single Doses of Rivaroxaban and Apixaban in Patients With Compensated Liver Cirrhosis[NCT04874428] | Phase 1 | 24 participants (Anticipated) | Interventional | 2021-05-19 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for dalteparin and Bacterial Infections
| Article | Year |
|---|---|
Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis.
Topics: Anticoagulants; Bacterial Infections; Bacterial Translocation; Biomarkers; DNA, Bacterial; Enoxapari | 2012 |